Published in Nucleic Acids Res on November 05, 2014
Hallmarks of cancer: the next generation. Cell (2011) 140.01
A method and server for predicting damaging missense mutations. Nat Methods (2010) 78.53
Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72
Comprehensive molecular portraits of human breast tumours. Nature (2012) 47.39
Comprehensive molecular characterization of human colon and rectal cancer. Nature (2012) 34.13
Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet (2008) 30.94
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res (2010) 25.55
Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature (2013) 20.16
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87
Comprehensive genomic characterization of squamous cell lung cancers. Nature (2012) 18.90
The accessible chromatin landscape of the human genome. Nature (2012) 16.86
Mutational landscape and significance across 12 major cancer types. Nature (2013) 14.91
Integrated genomic characterization of endometrial carcinoma. Nature (2013) 14.29
Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature (2013) 13.60
Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat (2007) 12.98
The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer (2004) 12.35
Discovery and saturation analysis of cancer genes across 21 tumour types. Nature (2014) 11.68
The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet (2013) 11.29
Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol (2008) 11.05
Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res (2011) 10.99
Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations. J Mol Biol (2002) 9.74
Effective energy function for proteins in solution. Proteins (1999) 9.44
FIMO: scanning for occurrences of a given motif. Bioinformatics (2011) 8.89
Comprehensive molecular characterization of urothelial bladder carcinoma. Nature (2014) 8.48
Bayesian statistical analysis of protein side-chain rotamer preferences. Protein Sci (1997) 7.92
ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules. Methods Enzymol (2011) 7.33
p53 mutations in cancer. Nat Cell Biol (2013) 5.18
The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther (2002) 4.73
The MDM2 gene amplification database. Nucleic Acids Res (1998) 4.64
An orientation-dependent hydrogen bonding potential improves prediction of specificity and structure for proteins and protein-protein complexes. J Mol Biol (2003) 4.63
Accumulation of driver and passenger mutations during tumor progression. Proc Natl Acad Sci U S A (2010) 4.47
Mutant p53: one name, many proteins. Genes Dev (2012) 4.33
Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A (2003) 4.06
A framework for the interpretation of de novo mutation in human disease. Nat Genet (2014) 4.00
Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA. Cell (1998) 3.79
High-resolution mapping of protein sequence-function relationships. Nat Methods (2010) 3.47
Structural basis for understanding oncogenic p53 mutations and designing rescue drugs. Proc Natl Acad Sci U S A (2006) 3.35
Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat Chem Biol (2011) 2.94
Thermodynamic stability of wild-type and mutant p53 core domain. Proc Natl Acad Sci U S A (1997) 2.90
In silico analysis of missense substitutions using sequence-alignment based methods. Hum Mutat (2008) 2.73
Characterization of genome-wide p53-binding sites upon stress response. Nucleic Acids Res (2008) 2.67
Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene (2000) 2.65
Role of conformational sampling in computing mutation-induced changes in protein structure and stability. Proteins (2010) 2.56
Genetic evidence and integration of various data sources for classifying uncertain variants into a single model. Hum Mutat (2008) 2.55
Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability. Proc Natl Acad Sci U S A (1998) 2.28
Oncogenic potential of the RUNX gene family: 'overview'. Oncogene (2004) 2.24
Interpreting missense variants: comparing computational methods in human disease genes CDKN2A, MLH1, MSH2, MECP2, and tyrosinase (TYR). Hum Mutat (2007) 2.16
Distinct p53 genomic binding patterns in normal and cancer-derived human cells. Cell Cycle (2011) 2.01
Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein. Hum Mutat (2002) 1.99
Comparative binding of p53 to its promoter and DNA recognition elements. J Mol Biol (2005) 1.96
A simple physical model for the prediction and design of protein-DNA interactions. J Mol Biol (2004) 1.90
Conformational locking upon cooperative assembly of notch transcription complexes. Structure (2012) 1.79
Systematic analysis of somatic mutations in phosphorylation signaling predicts novel cancer drivers. Mol Syst Biol (2013) 1.78
The leukemia-associated AML1 (Runx1)--CBF beta complex functions as a DNA-induced molecular clamp. Nat Struct Biol (2001) 1.77
Structures of p53 cancer mutants and mechanism of rescue by second-site suppressor mutations. J Biol Chem (2005) 1.67
Detailed computational study of p53 and p16: using evolutionary sequence analysis and disease-associated mutations to predict the functional consequences of allelic variants. Oncogene (2003) 1.67
A "solvated rotamer" approach to modeling water-mediated hydrogen bonds at protein-protein interfaces. Proteins (2005) 1.62
Effects of common cancer mutations on stability and DNA binding of full-length p53 compared with isolated core domains. J Biol Chem (2006) 1.61
Algorithm for prediction of tumour suppressor p53 affinity for binding sites in DNA. Nucleic Acids Res (2008) 1.58
Crystal structure of the p53 core domain bound to a full consensus site as a self-assembled tetramer. Structure (2010) 1.39
Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations. EMBO J (2000) 1.38
How many mutant p53 molecules are needed to inactivate a tetramer? Mol Cell Biol (2004) 1.35
Predicting the oncogenicity of missense mutations reported in the International Agency for Cancer Research (IARC) mutation database on p53. Hum Mutat (2005) 1.27
The SAAPdb web resource: a large-scale structural analysis of mutant proteins. Hum Mutat (2009) 1.12
Assessment of the optimization of affinity and specificity at protein-DNA interfaces. Nucleic Acids Res (2009) 1.07
Ferredoxin reductase: pharmacogenomic assessment in colorectal cancer. Cancer Res (2003) 0.94
Functional census of mutation sequence spaces: the example of p53 cancer rescue mutants. IEEE/ACM Trans Comput Biol Bioinform (2006) 0.90
Damaged DNA binding protein 2 plays a role in breast cancer cell growth. PLoS One (2008) 0.89
Structural and functional impact of cancer-related missense somatic mutations. J Mol Biol (2011) 0.89
Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes. Mol Cancer Res (2011) 0.89
Structure-energy-based predictions and network modelling of RASopathy and cancer missense mutations. Mol Syst Biol (2014) 0.86
Pliable DNA conformation of response elements bound to transcription factor p63. J Biol Chem (2012) 0.86
Structural assessment of single amino acid mutations: application to TP53 function. Hum Mutat (2006) 0.83
Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation. J Biol Chem (2010) 0.80